Recently discovered adipokines and cardio-metabolic comorbidities in childhood obesity

Area of Science:

• Endocrinology
• Metabolic Syndrome
• Adipose Tissue Biology

Background:

• White adipose tissue (WAT) development in early life influences its inflammatory state and endocrine function.
• Obesity-related cardio-metabolic abnormalities are significantly impacted by WAT-derived adipokines.

Purpose of the Study:

• To review recently identified adipokines and their roles in obesity pathogenesis.
• To examine the adaptive responses of these adipokines to body weight changes.
• To assess their potential as predictive markers for cardio-metabolic risk and therapeutic response.

Main Methods:

• Literature review of recent studies on novel adipokines.
• Analysis of the role of specific adipokines (A-FABP, chemerin, FGF-21, lipocalin-2, omentin-1, vaspin) in obesity.
• Evaluation of evidence linking adipokines to cardio-metabolic abnormalities.

Main Results:

• Adipocyte-fatty acid-binding protein (A-FABP), chemerin, and fibroblast growth factor-21 (FGF-21) show consistent evidence of a pathogenic role in obesity.
• These adipokines are implicated in the development of cardio-metabolic abnormalities associated with obesity.
• Their adaptive responses to body weight fluctuations are also discussed.

Conclusions:

• A-FABP, chemerin, and FGF-21 are key players in the pathogenesis of obesity and associated metabolic disorders.
• Further large-scale population studies are required to validate their utility in predicting cardio-metabolic risk.
• These adipokines may serve as future biomarkers for monitoring treatment efficacy in obesity-related conditions.